The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it.

Moderna’s CEO is defending a plan to more than quadruple the company’s COVID-19 vaccine price.

Moderna’s stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing another potential preventive shot for a deadly form of skin cancer.

Supply problems have again forced Moderna to delay some COVID-19 vaccine deliveries, a move that surprised Wall Street and contributed to a disappointing third quarter.

Moderna is scaling back expectations for the number of COVID-19 vaccine deliveries it expects to make this year and the revenue it will record from them.